Pathological and clinical aspects of alpha/beta synuclein in Parkinsons disease and related disorders

Michael Tolmasov, Ruth Djaldetti, Nirit Lev, Yossi Gilgun-Sherki

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Parkinsons disease (PD) and related synucleinopathies are characterized by extensive neuronal cell loss, which is potentially triggered by α-synuclein misfolding and aggregation. Therefore it is reasonable to suggest that treatments targeting α-synuclein could reduce its levels and toxicity, rescue neuronal cells and halt the neurodegeneration process. Several approaches to decrease α-synuclein levels were employed thus far, mainly by using β-synuclein, another protein from the same family, or immunotherapies. These treatments demonstrated some positive results in preclinical studies, which may pave the road to the development of new promising disease-modifying therapies (DMTs). This approach should be further examined in preclinical and clinical settings, together with a clear process in order to advance candidates, enable the ability to define when there are target engagements and to detect what is a meaningful pharmacological response, and how it will be translated in clinical efficacy.

Original languageEnglish
Pages (from-to)505-513
Number of pages9
JournalExpert Review of Neurotherapeutics
Issue number5
StatePublished - 3 May 2016
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.


  • Parkinson's disease
  • disease-modifying therapy
  • immunotherapy
  • multiple system atrophy
  • α-synuclein
  • β-synuclein


Dive into the research topics of 'Pathological and clinical aspects of alpha/beta synuclein in Parkinsons disease and related disorders'. Together they form a unique fingerprint.

Cite this